Evidence map›Paper›PMID 36633367›Full record

ArticlePublic health reports (Washington, D.C. : 1974)

Cascade of Care for Hepatitis C Virus Infection Among Young Adults Who Inject Drugs in a Rural County in New Mexico.

Mary D Carmody, Katherine Wagner, Birgitta Bizstray, Karla Thornton, Phillip Fiuty, Aubrey Del Rosario, Eyasu Teshale, Kimberly Page

Open access · greenAbstract read
In one paragraph

Article in Public health reports (Washington, D.C. : 1974). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 10 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Mary D CarmodyDepartment of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, NM, USA.
Katherine WagnerDepartment of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, NM, USA.
Birgitta BizstrayDepartment of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, NM, USA.
Karla ThorntonDepartment of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, NM, USA.
Phillip FiutyThe Mountain Center, Espanola, NM, USA.
Aubrey Del RosarioDepartment of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, NM, USA.
Eyasu TeshaleEpidemiology and Surveillance Branch, Division of Viral Hepatitis, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Kimberly PageDepartment of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, NM, USA.ORCID 0000-0002-7120-1673
University of New Mexico · USCenters for Disease Control and Prevention · US

Funding

UNM HSC Clinical and Translational Science CenterUL1TR001449 · NCATS · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI CAMPEN, MATTHEW J, PANDHI, NANCY · 2015 to 2024
$36.9M
ACL HHS U18PS004568NCATS NIH HHS UL1 TR001449NCHHSTP CDC HHS U18 PS004568
6 · The paper itself

Abstract

objectiveTreatment for hepatitis C virus (HCV) infection is highly effective; however, people who inject drugs (PWID), the population most affected by HCV, may encounter barriers to treatment. We examined the cascade of care for HCV infection among young adult PWID in northern New Mexico, to help identify gaps and opportunities for HCV treatment intervention.

methodsYoung adults (aged 18-29 y) who self-reported injection drug use in the past 90 days were tested for HCV antibodies (anti-HCV) and HCV RNA. We asked participants with detectable RNA to participate in an HCV education session, prior to a referral to a local health care provider for treatment follow-up, and to return for follow-up HCV testing quarterly for 1 year. We measured the cascade of care milestones ranging from the start of screening to achievement of sustained virologic response (SVR).

resultsAmong 238 participants, the median age was 26 years and 133 (55.9%) were men. Most (90.3%) identified as Hispanic. Of 109 RNA-positive participants included in the cascade of care assessment, 84 (77.1%) received their results, 82 (75.2%) participated in the HCV education session, 61 (56.0%) were linked to care through a medical appointment, 27 (24.8%) attended the HCV treatment appointment, 13 (11.9%) attended their follow-up appointment, 6 (5.5%) initiated treatment, 3 (2.8%) completed treatment, and 1 (0.9%) achieved SVR.

conclusionsWe observed a steeply declining level of engagement at each milestone step of the cascade of care after detection of HCV infection, resulting in a suboptimal level of HCV treatment and cure. Programs that can streamline testing and expand access to treatment from trusted health care providers are needed to improve the engagement of PWID in HCV treatment.

Indexed as

Hepatitis CSubstance Abuse, IntravenousAdultAntiviral AgentsFemaleHepacivirusHumansMaleNew MexicoRNAYoung AdultAntiviral AgentsRNAdrug usehepatitis C treatment

Identifiers

PMID36633367
PMCPMC10576476
OpenAlexW4315754258

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.